|
DE4337611A1
(de)
|
1993-11-04 |
1995-05-11 |
Boehringer Ingelheim Kg |
Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
|
|
CN1087725C
(zh)
|
1994-03-25 |
2002-07-17 |
同位素技术有限公司 |
用氘代方法增强药物效果
|
|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
|
DE69921358T2
(de)
*
|
1998-12-23 |
2006-03-09 |
Bristol-Myers Squibb Pharma Co. |
Stickstoffhaltige heterobicyclen als faktor-xa-hemmer
|
|
MXPA03007623A
(es)
|
2001-02-26 |
2003-12-04 |
Tanabe Seiyaku Co |
Derivado de piridopirimidina o naftiridina.
|
|
JP2004083587A
(ja)
|
2002-08-06 |
2004-03-18 |
Tanabe Seiyaku Co Ltd |
医薬組成物
|
|
ITFR20030005U1
(it)
|
2003-03-17 |
2003-06-16 |
C D R |
Sistema di protezione solare (frangisole f1)
|
|
JP2010208945A
(ja)
|
2007-06-01 |
2010-09-24 |
Mitsubishi Tanabe Pharma Corp |
複素環化合物
|
|
EP2370437B1
(en)
|
2008-11-25 |
2013-09-04 |
Nerviano Medical Sciences S.r.l. |
Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
|
|
SG10201407012XA
(en)
|
2009-10-29 |
2014-11-27 |
Genosco |
Kinase inhibitors
|
|
US8541418B2
(en)
|
2009-12-23 |
2013-09-24 |
Elan Pharmaceutical, Inc. |
Inhibitors of polo-like kinase
|
|
US20130178475A1
(en)
|
2010-03-17 |
2013-07-11 |
Ironwood Pharmaceuticals, Inc. |
sGC STIMULATORS
|
|
US9242981B2
(en)
*
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
AU2011376721B2
(en)
|
2011-09-16 |
2017-06-08 |
Sanofi |
Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
|
|
CA2896731A1
(en)
|
2012-12-28 |
2014-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
|
|
CN104311555B
(zh)
|
2014-09-19 |
2016-04-20 |
广东东阳光药业有限公司 |
吡唑并哌啶酮类化合物及其组合物及用途
|
|
US9763922B2
(en)
|
2014-11-27 |
2017-09-19 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
US10189841B2
(en)
*
|
2015-11-20 |
2019-01-29 |
Forma Therapeutics, Inc. |
Purinones as ubiquitin-specific protease 1 inhibitors
|
|
JP7114076B2
(ja)
|
2015-12-22 |
2022-08-08 |
シャイ・セラピューティクス・エルエルシー |
がん及び炎症性疾患の処置のための化合物
|
|
EP3464286B1
(en)
|
2016-05-24 |
2021-08-18 |
Genentech, Inc. |
Pyrazolopyridine derivatives for the treatment of cancer
|
|
JP7514005B2
(ja)
|
2017-06-21 |
2024-07-10 |
シャイ・セラピューティクス・エルエルシー |
がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
|
|
WO2019089216A1
(en)
|
2017-11-01 |
2019-05-09 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancers
|
|
BR112021010715A2
(pt)
*
|
2018-12-20 |
2021-11-16 |
Ksq Therapeutics Inc |
Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1)
|
|
JP7553450B2
(ja)
*
|
2018-12-28 |
2024-09-18 |
フォーマ セラピューティクス，インコーポレイテッド |
ユビキチン特異的プロテアーゼ１を阻害するための組成物
|
|
CA3168009A1
(en)
*
|
2020-02-14 |
2021-08-19 |
KSQ Therapeutics, Inc. |
Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
|
|
EP4161494A4
(en)
|
2020-06-02 |
2024-07-17 |
KSQ Therapeutics, Inc. |
NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS
|
|
KR20230098186A
(ko)
|
2020-10-30 |
2023-07-03 |
케이에스큐 세러퓨틱스 인코포레이티드 |
치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
|
|
TW202246255A
(zh)
|
2021-02-12 |
2022-12-01 |
美商傳達治療有限公司 |
Ｃｄｋ抑制劑及其使用方法
|
|
US20240182481A1
(en)
|
2021-02-15 |
2024-06-06 |
Tango Therapeutics, Inc. |
Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
|
|
AU2022238886A1
(en)
|
2021-03-17 |
2023-09-14 |
Medivir Ab |
Purine derivatives as anticancer agents
|
|
WO2022199652A1
(en)
|
2021-03-24 |
2022-09-29 |
Impact Therapeutics (Shanghai) , Inc |
Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
|
|
MX2023011709A
(es)
|
2021-04-07 |
2023-10-12 |
Forma Therapeutics Inc |
Inhibidor de la proteasa 1 especifica de ubiquitina (usp1).
|
|
EP4321515A4
(en)
|
2021-04-09 |
2025-06-25 |
Hainan Simcere Zaiming Pharmaceutical Co., Ltd. |
UBIQUITIN-SPECIFIC PROTEASE-1 INHIBITOR
|
|
EP4430041A4
(en)
|
2021-11-12 |
2025-09-24 |
Insilico Medicine Ip Ltd |
SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) AND THEIR USES
|
|
CR20240191A
(es)
|
2021-11-12 |
2024-09-13 |
Insilico Medicine Ip Ltd |
Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
|
|
GEAP202416531A
(en)
|
2021-11-12 |
2024-10-28 |
Insilico Medicine Ip Ltd |
Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
|
|
WO2024086790A1
(en)
|
2022-10-21 |
2024-04-25 |
Exelixis, Inc. |
4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS
|